Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
M&A activity
confidence 98%
filed 2026-07-06
EX-99.1
The press release announces Descartes' acquisition of Drivin, a Latin American last-mile delivery management platform, for approximately US $30 million in upfront cash consideration plus up to US $5 million in performance-based earn-out. This is a material acquisition that expands Descartes' AI-powered logistics capabilities and geographic reach, directly fitting the ma_activity category (Item 1.01 / 2.01 equivalent for foreign issuers).
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-06
Item 8.01
The filing discloses a merger transaction between Cross Country Healthcare and KL Criss Cross Intermediate, LLC, with a special stockholder meeting scheduled for July 16, 2026, and expected closing in Q3 2026. The Item 8.01 disclosure supplements the proxy statement with supplemental disclosures regarding executive interests, financial analyses, and litigation relating to the merger. This is a material acquisition/change of control event that would significantly affect a reasonable investor's assessment of the registrant.
View raw filing on EDGAR →
6-K
Governance Other
confidence 75%
filed 2026-07-06
ICICI Bank disclosed entry into a Letter of Undertaking with Prudential Corporation Holdings Limited on July 4, 2026, governing governance and control rights in their joint subsidiary ICICI Prudential Life Insurance Company Limited during Prudential's proposed reclassification from promoter to investor status. The undertaking restricts Prudential's voting on special resolutions, requires resignation of its nominee director, and modifies future director nomination rights—material governance changes affecting the subsidiary's management structure and the inter-se rights of joint promoters.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-06
Item 8.01
Figure Technology Solutions announced a private offering of $600 million in aggregate principal amount of senior notes due 2031. This is a creation of a new direct financial obligation through debt issuance. While the proceeds are intended to fund the Kiavi Acquisition, the primary disclosed event is the issuance of the Notes themselves, which is a material capital-raising transaction typical of Item 2.03 debt issuance disclosures.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-06
Item 1.01
Clarivate entered into a Stock and Asset Purchase Agreement to sell its Life Sciences and Healthcare business to an Altaris affiliate for $600 million in aggregate consideration, comprising cash, deferred payments, and a senior note.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-07-06
Item 5.02
Clarivate entered into a retention agreement with Henry Levy, President of Life Sciences & Healthcare, providing for full vesting of unvested RSUs upon transaction closing, cancellation of performance share units, and severance payments of 18 months' base salary and target bonus plus COBRA payments if terminated without cause within six months post-closing.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
The filing discloses the appointment of John M. Lutz, age 64, to ePlus's Board of Directors on July 6, 2026, increasing the board size from eight to nine directors. Mr. Lutz was also appointed to the Audit Committee and Compensation Committee. The Board determined he is an independent director under Nasdaq rules. This is a clear executive appointment event, material to investors as board composition and committee assignments affect governance and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-06
Item 5.02
Steven Dorwart's appointment as President, Connectivity and Cloud Solutions effective immediately is the principal disclosed action. While Jason Phillips' retirement is also mentioned, the filing centers on the succession and appointment of Dorwart to a key executive role overseeing a major business segment. The press release emphasizes Dorwart's qualifications, experience, and strategic importance to the company's growth trajectory, making the appointment the salient event.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-06
Item 7.01
The filing discloses a previously announced recommended cash acquisition by Ingredion of Tate & Lyle PLC, with the Scheme Document published on July 3, 2026 and shareholder meetings scheduled for July 28, 2026. This represents a material acquisition activity requiring disclosure under Item 1.01 or related M&A provisions, disclosed here under Item 7.01 as a regulatory FD disclosure regarding the Scheme Document and shareholder voting process.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
Stephen R. Curley was appointed to the boards of Eagle Bancorp and its subsidiary EagleBank effective July 6, 2026, in connection with his previously announced position as President and Chief Executive Officer. The appointment of a CEO to the board is a material executive appointment that would affect a reasonable investor's assessment of the company's leadership structure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-06
EX-99.1
This press release discloses material operational and regulatory milestones for New Found Gold's flagship Queensway Gold Project and Pine Cove mill facility. The key disclosures are: (1) receipt of a referral for an Environmental Preview Report (EPR) from the NL Minister of Environment following environmental registration review, triggering a defined regulatory timeline; (2) receipt of a mill conversion permit amendment for Pine Cove to convert from a 700 tpd flotation circuit to a 1,400 tpd Gravity-CIL circuit; and (3) ongoing EPCM work with an objective to send first Queensway Phase 1 material to the mill in Q4 2027 and achieve commercial production in H2 2028. These are material operational and regulatory developments affecting the Company's development timeline and capital deployment, but do not fit a discrete event category (not M&A, not a restatement, not an impairment, not a workforce reduction). The disclosure is clearly operational/strategic in nature and would affect a reasonable investor's assessment of project advancement risk and timing.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-06
EX-99.1
Integra Resources announced an updated Feasibility Study and Life-of-Mine Plan for the Florida Canyon Mine, extending mine life from 2030 to 2033, increasing annual gold production from 70 Koz to 82 Koz, and planning $92M in growth capital investments with an updated NPV of $601M.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-06
Item 5.02
Kevin "Duke" Pitts resigned on July 1st, 2026 from three significant roles: President, Chief Operating Officer, and Board member. The disclosure centers on the departure itself, with the company noting the positions will remain vacant. This is a material executive departure affecting senior operational leadership.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-06
The 6-K discloses the final voting results from Tungray Technologies' 2026 annual general meeting held July 1, 2026, including re-election of five directors (Wanjun Yao, Jingan Tang, Kevin D. Vassily, David Ping Li, and Weston Twigg) and ratification of Guangdong Prouden CPAs GP as independent auditor. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, reporting the outcome of shareholder votes on material governance matters.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 35%
filed 2026-07-06
Item 1.01
While the Tenth Amendment technically amends an existing credit facility rather than creating new debt, the substance reveals severe financial distress: the company capitalized accrued interest into principal, deferred a $9M+ payment, reduced minimum liquidity covenants, and agreed to pursue asset sales or restructuring by July 31, 2026. The lender-controlled strategic committee and extensive operational restrictions signal covenant renegotiation under duress. This is more accurately characterized as a covenant_breach or restructuring event, but the 8-K Item 1.01 classification and the amendment's material modification of debt terms place it closest to debt_issuance in the taxonomy, though covenant_breach may be more precise if the original covenant was breached.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-07-06
EX-99.1
This is a press release disclosing NIU's second quarter 2026 sales volume results, presented in a tabular format comparing 2Q 2026 (434,687 units) to 2Q 2025 (350,090 units) and first-half results. Although styled as a "sales volume update" rather than a full earnings release, it provides quantitative financial performance metrics for the quarter and is issued as a public announcement of results. The disclosure includes management commentary on market performance, product launches, and strategic initiatives, consistent with an earnings announcement. Sales volume is a key operational metric that would affect a reasonable investor's assessment of the company's financial performance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
Kyndryl appointed Ellen Johnson as Chief Financial Officer effective approximately August 6, 2026, and Andrew Bonzani as General Counsel and Secretary effective July 1, 2026. Both appointments include compensatory arrangements reflecting their senior leadership roles.
View raw filing on EDGAR →
8-K
Earnings release
confidence 85%
filed 2026-07-06
Item 2.02
This Item 2.02 disclosure provides preliminary financial results for Q2 2026, specifically flagging an expected acquired IPR&D charge of approximately $127 million that will negatively impact both GAAP and non-GAAP net income per diluted share by approximately $1.00. While the full earnings release is not attached, the disclosure of preliminary quarterly financial results and their expected impact on per-share metrics is characteristic of an earnings-related disclosure under Item 2.02, even though the company notes results have not been finalized.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 94%
filed 2026-07-06
Item 2.03
ProFrac entered into a new $300 million asset-based revolving credit facility with Eclipse Business Capital LLC on July 1, 2026, which refinanced and replaced its prior $275 million JPMorgan Chase facility. The new facility extends maturity to July 2030 and improves borrowing base terms, representing a material creation of a new direct financial obligation.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-06
Item 8.01
The filing discloses two material transactions: (1) a 20-year lease agreement with Anthropic generating approximately $19 billion in contracted revenue over the initial term, and (2) the sale of TeraWulf's 50.1% ownership interest in the Abernathy Joint Venture to Fluidstack for approximately $530 million in aggregate consideration. Both transactions are significant capital events that materially affect the company's financial position, revenue visibility, and strategic direction. The Abernathy sale is explicitly a disposition of equity interests, and the Anthropic lease represents a major long-term revenue commitment that would affect investor assessment of the registrant's future cash flows and growth prospects.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-06
Item 7.01
Element Solutions Inc. entered into a definitive Agreement and Plan of Merger on July 6, 2026, whereby Solstice Advanced Materials will acquire Element Solutions in a cash-and-stock transaction valued at approximately $14.5 billion (including assumption of net debt). The transaction structure provides $10.00 cash plus 0.500 Solstice shares per Element share, with expected closing in H1 2027, subject to customary conditions including regulatory and shareholder approvals.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-06
Item 2.01
Liminatus Pharma completed the acquisition of InnocsAI LLC on July 2, 2026, pursuant to an Amended and Restated Merger Agreement entered into on June 29, 2026. The transaction involved approximately 1.6 billion shares of merger consideration comprising 19.99% common stock and Series A Non-Voting Convertible Preferred Stock, along with registration rights and non-compete agreements.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-06
EX-99.1
The exhibit announces the appointment of Rob Slack, PhD, as Chief Scientific Officer of Vicore Pharma, effective immediately. This is a material executive appointment at a clinical-stage biopharmaceutical company, where the Chief Scientific Officer role is critical to research strategy and pipeline development. The disclosure also notes that the prior CSO, Johan Raud, is transitioning to Senior Advisor, which is a secondary departure element but the primary disclosed action is Slack's appointment to the CSO position.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-06
Item 5.02
Sarkees John Nahas, a member of the Company's Board of Directors, resigned effective July 1, 2026. The disclosure explicitly states the resignation date and confirms no disagreement with the Company, which is a standard departure disclosure. Board composition changes are material to investors assessing governance and leadership continuity.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-06
Item 5.07
This Item 5.07 filing discloses the results of an extraordinary general meeting of shareholders held on July 6, 2026, where Spring Valley Acquisition Corp. III shareholders voted on seven proposals, including approval of a business combination with General Fusion Inc., continuation from Cayman Islands to British Columbia, governance amendments, and director elections. All proposals were approved with detailed voting tallies provided for each. This is a classic shareholder vote results disclosure under Item 5.07.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-06
Item 3.01
CytoSorbents received a written notice from Nasdaq on June 29, 2026, that it failed to comply with Nasdaq Listing Rule 5550(b)(2) due to its Market Value of Listed Securities falling below the $35 million minimum required for continued listing on the Nasdaq Capital Market. The company has been given a 180-day grace period (until December 28, 2026) to regain compliance, with explicit warning that failure to do so will result in delisting notification and potential loss of listing. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-06
Item 8.01
ClearSign Technologies filed a prospectus supplement on July 6, 2026 to recommence an "at the market" offering under which it may sell up to $6,875,000 in common stock shares pursuant to an ATM agreement with H.C. Wainwright & Co. This is a classic dilutive equity issuance under Rule 415, material to investors as it signals potential shareholder dilution and the company's capital-raising needs.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-07-06
Item 5.07
Two Harbors' stockholders voted to approve the merger with CrossCountry Mortgage at a special meeting held on July 2, 2026, with 54,297,767 votes in favor and 23,570,833 against. The merger consideration is $12.00 per share in cash plus a pro-rated stub dividend, and completion is now contingent on satisfaction of remaining regulatory approvals.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-06
The filing discloses shareholder approval and effective implementation of amendments to the Company's Amended and Restated Memorandum of Association and Articles of Association, including a doubling of authorized share capital from CI$12.5 million to CI$25 million and amendments regarding share repurchase authority and treasury share treatment. While shareholder vote results are typically classified as shareholder_vote_results, this filing emphasizes the effective implementation of the governance amendments themselves rather than reporting the vote outcome (which was disclosed in the Prior Form 8-K of June 5, 2026). The material governance changes—particularly the doubling of authorized shares and new share repurchase authority—constitute a governance event affecting the company's capital structure and shareholder rights.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-06
Item 5.02
Steven Kemps, Executive Vice President and Chief Legal Officer, notified the Company on July 1, 2026 of his decision to retire effective December 31, 2026. The Company is launching a search for his successor.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-06
Item 1.01
Meridian3 Industrials Acquisition Corp consummated its IPO on July 1, 2026, raising $201.25 million in gross proceeds through entry into multiple material definitive agreements including underwriting, warrant, registration rights, and private placement agreements.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 3.02
The Company completed an unregistered private placement of 5,500,000 warrants to the Sponsor and Cantor Fitzgerald at $1.00 per warrant, generating $5.5 million in gross proceeds, with the warrants exercisable into Class A Ordinary Shares.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
Five individuals—Professor Dr Sir Ralf Speth, Dr. John Llewellyn, Steven G. Osgood, Hideyuki Nakashima, and Steven Robert Armstrong—were appointed to the board of directors effective July 1, 2026 in connection with the IPO, with four designated as independent directors and committee assignments to the Audit and Compensation Committees.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-06
Item 1.01
Optimum Communications entered into a Second Amended and Restated Credit Agreement establishing an incremental term loan commitment of $250 million with a fixed 9.000% interest rate maturing November 25, 2028.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-07-06
EX-99.1
Dylan Marx has been appointed as Chief Executive Officer of Recurrent Energy, the Company's global project development subsidiary, effective immediately. While Ismael Guerrero's departure from the CEO role is also disclosed, the principal action announced is the appointment of Marx to lead a material subsidiary. The filing emphasizes Marx's qualifications and the seamless transition plan, consistent with an executive appointment disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-06
Item 2.02
This Item 2.02 disclosure presents preliminary unaudited estimates of Rivian's Q2 2026 financial results, including total consolidated revenues (estimated $1.55–$1.65 billion, up from $1.30 billion in Q2 2025) and cash position ($5.3 billion as of June 30, 2026). The disclosure explicitly states these are "preliminary estimates of selected financial information" and explains the drivers of revenue growth (increased vehicle deliveries, higher commercial van mix, software services, and regulatory credits). This is a classic earnings release format—preliminary financial results disclosed via 8-K Item 2.02 ahead of full quarterly filings—and is material to investors assessing the company's operational performance and financial trajectory.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-06
Item 1.01
Element Solutions Inc entered into an Agreement and Plan of Merger with Solstice Advanced Materials Inc on July 6, 2026, whereby Element Solutions will merge with Solstice subsidiaries in a two-step transaction, with Element Solutions stockholders receiving 0.500 shares of Solstice Common Stock and $10.00 cash per share.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-07-06
Item 5.02
Element Solutions memorialized a letter agreement with John E. Capps, former Executive Vice President, General Counsel and Secretary, confirming his continued entitlements under his Change in Control Agreement, including receipt of annual bonus and severance at levels to which he was entitled in connection with the proposed merger.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-06
Item 5.03
This disclosure describes a 5-for-1 reverse stock split effected through amendments to the Declaration of Trust, reducing outstanding shares from ~647.64 million to ~129.53 million. While a reverse split is a governance/structural action (amendment to articles), it is material to investors as it affects share count, trading mechanics, and potential delisting implications. The event does not fit the specific governance categories (exec appointment/departure, compensation, shareholder vote results) but is clearly a material governance matter warranting disclosure under Item 5.03.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-07-06
Item 1.01
GridAI Technologies entered into a securities purchase agreement on July 1, 2026, to sell 664,598 shares of common stock, pre-funded warrants, and common stock purchase warrants for approximately $8.5 million in gross proceeds through a private placement relying on Section 4(a)(2) exemption. The transaction includes substantial warrant components (pre-funded warrants exercisable at $0.0001 and common warrants exercisable at $4.47) that significantly increase dilution potential.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-06
Item 1.01
Arbor Realty Trust completed the issuance and sale of $375 million aggregate principal amount of 6.25% Convertible Senior Notes due 2029 on July 6, 2026. The convertible notes represent a material creation of a new direct financial obligation, with proceeds to be used for redemption of existing debt and share repurchases.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-06
EX-99.1
Canaan announced completion of a transfer from Nasdaq Global Market to Nasdaq Capital Market due to failure to maintain the minimum bid price of $1.00 for 30 consecutive business days. The company received a non-compliance notice on January 14, 2026, and has applied for an additional 180-day compliance period. This disclosure directly addresses delisting risk and the company's efforts to regain compliance with continued listing standards.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
Hope Lundt was appointed to the Board of Directors of EWSB Bancorp, Inc. and its subsidiary on July 1, 2026, and assigned to the Audit Committee and Governance and Nominating Committee. This is a clear director appointment, the principal disclosed action. The disclosure of standard non-employee director compensation arrangements is incidental to the appointment itself.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-06
Item 2.02
This is a straightforward earnings release disclosing Q1 2026 financial results for Exyn Technologies. The filing explicitly states "On July 6, 2026, Exyn Technologies, Inc. issued a press release announcing its financial results for the three months ended March 31, 2026" and furnishes the press release as Exhibit 99.1. The exhibit contains detailed financial metrics including revenue ($1.19M), gross profit ($0.50M), operating expenses ($3.38M), and net loss ($3.24M), along with strategic highlights including the company's recent IPO completion. This is a material disclosure affecting investor assessment of the registrant's financial performance and operational status.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-06
EX-99.1
Standard Lithium disclosed the issuance of 3,139,330 common shares under its at-the-market (ATM) equity program during Q2 2026, generating gross proceeds of US$11.3 million. ATM offerings are unregistered equity issuances that dilute existing shareholders and are material capital-raising events, particularly for development-stage companies like Standard Lithium.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-06
Item 8.01
The filing discloses a material regulatory setback to a pending merger transaction: the New Mexico Public Regulation Commission issued a final order on July 2, 2026, voiding the $400 million PIPE Transaction (equity financing for the Merger) as undertaken without prior NMPRC authorization, imposing a $300,000 aggregate penalty, and requiring a compliance report within 45 days. The NMPRC also stayed the procedural schedule for the Merger Application pending review of the compliance filing. This regulatory action materially affects the consummation and financing of the Merger between TXNM and Blackstone Infrastructure Partners, making it a significant M&A development.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-06
Item 5.07
Barnwell Industries held its Annual Meeting of Stockholders on June 29, 2026, at which shareholders voted on six proposals: director elections, amendments to the 2018 Equity Incentive Plan, ratification of prior equity awards, advisory say-on-pay vote, frequency of future say-on-pay votes, and ratification of the independent auditor (Weaver & Tidwell, L.L.P.). All proposals passed.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-06
EX-99.1
This press release announces the extension of a time charter contract for the M/T Briolette with Aramco Trading for 35 months at US$37,700 per day, expected to generate approximately US$39 million in gross revenue. While the disclosure is operational in nature (a material commercial contract), it does not fit the specific event types of debt issuance, M&A activity, or other named categories. The announcement is material to investors as it demonstrates significant contracted revenue backlog (exceeding $500 million), extends charter coverage through 2028-2029, and provides earnings visibility—metrics that would affect a reasonable investor's assessment of the company's financial position and operational strength.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-06
Item 1.01
Crinetics Pharmaceuticals entered into a definitive merger agreement with Vertex Pharmaceuticals on July 6, 2026, under which Vertex will acquire Crinetics for $85.00 per share in cash, representing approximately $10.0 billion in total equity value (or $8.8 billion net of cash). The transaction is expected to close in Q3 2026, subject to regulatory and shareholder approvals, and adds significant commercial and pipeline assets including PALSONIFY and atumelnant with approximately $5 billion peak sales potential to Vertex's portfolio.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-06
EX-99.1
This press release discloses the results of Inventiva's Combined Shareholders' General Meeting held on June 30, 2026, presenting detailed voting outcomes for 40 ordinary and extraordinary resolutions. The document explicitly states "All the resolutions submitted to vote have been adopted by the shareholders, with the exception of the 31st resolution," and provides comprehensive vote tallies including approval percentages, abstentions, and quorum information. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, material to investors as it confirms shareholder approval of governance matters including compensation policies and board-related decisions.
View raw filing on EDGAR →